Journal Article

Metallothionein modulates the carcinogenicity of <i>N</i>-butyl-<i>N</i>-(4-hydroxybutyl)nitrosamine in mice

Yukihiro Kondo, Seiichiro Himeno, Wakako Endo, Masaharu Mita, Yasutomo Suzuki, Kaoru Nemoto, Masao Akimoto, John S. Lazo and Nobumasa Imura

in Carcinogenesis

Volume 20, issue 8, pages 1625-1628
Published in print August 1999 | ISSN: 0143-3334
Published online August 1999 | e-ISSN: 1460-2180 | DOI: http://dx.doi.org/10.1093/carcin/20.8.1625
Metallothionein modulates the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine in mice

More Like This

Show all results sharing this subject:

  • Clinical Cytogenetics and Molecular Genetics

GO

Show Summary Details

Preview

We examined the carcinogenicity of N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) in transgenic mice deficient in the metallothionein (MT) I and II genes and in control (129/Sv) mice. Both strains of mice were given BBN for 8 weeks with or without Zn treatment. All mice were killed at 12 weeks after the cessation of BBN administration. BBN induced bladder tumors in 75% of MT null mice and in 43% of 129/Sv mice. The average number of bladder tumors per mouse was significantly higher in MT null mice (1.18 ± 0.27) than in 129/Sv mice (0.43 ± 0.20). Zn treatment suppressed the carcinogenicity of BBN in 129/Sv mice but not in MT null mice. Histopathological examination of the tumors revealed that the malignant potential of bladder tumors in 129/Sv mice was greater than that in MT null mice. These results indicate that MT is an important modulator of carcinogenicity of BBN in the bladder of mice.

Keywords: BBN, N-butyl-N-(4-hydroxybutyl)nitrosamine; DMBA, 7,12-dimethylbenz[a]anthracene; MT, metallothionein.

Journal Article.  2213 words.  Illustrated.

Subjects: Clinical Cytogenetics and Molecular Genetics

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.